Skip to main content Accessibility help
×
Home

Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France

  • Magali Morelle (a1), Elodie Haslé (a1), Isabelle Treilleux (a1), Jean-Philippe Michot (a1), Thomas Bachelot (a1), Frédérique Penault-Llorca (a2) and Marie-Odile Carrère (a3)...

Abstract

Objectives: A cost-effectiveness analysis was conducted comparing diagnostic strategies for determining the HER2 status of invasive breast carcinomas, as an indication for trastuzumab at metastatic relapse.

Methods: A decision tree compared five strategies distinguished by (i) the use of immunohistochemical (IHC) and/or fluorescent in situ hybridization (FISH) techniques, and (ii) the test schedule (at initial diagnosis or metastatic relapse). Most cost and effectiveness data came from a French multicentric study of 2,045 patients from eight hospitals. We were not able to select final criteria for trastuzumab effectiveness, because published data rely on IHC techniques not used in France (i.e., HercepTest). We, therefore, selected two intermediate criteria for inappropriate treatment at relapse, that is, patients with HER2-amplified tumors not receiving trastuzumab (Criterion 1) and HER2-nonamplified tumors improperly treated with trastuzumab (Criterion 2). Sensitivity analyses were then performed to assess the robustness of the results to (i) discount rate, (ii) cost of FISH, and (iii) tissue fixation technique.

Results: The strategy using IHC at diagnosis was dominated by the four other strategies. Among these approaches, the only efficient strategy for both criteria was IHC used alone at metastatic relapse; strategies using FISH, or IHC followed by FISH on IHC2+ cases were efficient for Criterion 1, whereas IHC followed by FISH on IHC2+ and 3+ cases was efficient for Criterion 2.

Conclusions: Determining HER2 status at diagnosis, as an indication for trastuzumab at metastatic relapse, incurs substantial incremental costs, which do not appear to be justified. No other strategy can be excluded at first.

Copyright

References

Hide All
Bachelot T, Ray-Coquard I, Coeffic D. 2002 Adjuvant therapy for breast cancer patients: Treatment decision tree from a French cancer network. Bull Cancer. 89: 897903.
Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. 1982 A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med. 73: 889897.
Bilous M, Dowsett M, Hanna W, et al. 2003 Current perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol. 16: 173182.
Denoux Y, Arnould L, Fiche M. 2003 HER2 gene amplification assay: Is CISH an alternative to FISH? Annal Pathol. 23: 617622.
Di Leo A, Dowsett M, Horten B, et al. 2002 Current status of HER2 testing. Oncology. 63 (Suppl 1): 2532.
Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. 1997. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press;
Early Breast Cancer Trialists' Collaborative Group. 1998 Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet. 352: 930942.
Early Breast Cancer Trialists' Collaborative Group. 1998 Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 351: 14511467.
Elkin EB, Weinstein MC, Winer EP, et al. 2004 HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol. 22: 854863.
Falo C, Moreno A, Lloveras B, et al. 2003 Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas. Am J Clin Oncol. 26: 465470.
Fisher B, Anderson S, Bryant J. 2002 Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 347: 12331241.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. 1999 Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 17: 19741982.
Kakar S, Puangsuvan N, Stevens JM, et al. 2000 HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival. Mol Diagn. 5: 199207.
Lebeau A, Deimling D, Silverman ML, et al. 2001 Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 19: 354363.
Loprinzi CL, Thome SD. 2001 Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol. 19: 972979.
Mason J. 1997 The generalisability of pharmacoeconomics studies. Pharmacoeconomics. 11: 503514.
Slamon DJ, Clark GM, Jones LA, et al. 1987 Human breast cancer: Correlation of relapse and survival with amplification of the HER2/Neu oncogene. Science. 235: 177182.
Slamon DJ, Godolphin W, Jones LA, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244: 70712.
Slamon DJ, Leyland-Jones B, Shak S, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344: 783792.
Spath HM, Carrere MO, Fervers B, Philip T. 1999 Analysis of the eligibility of published economic evaluations for transfer to a given health care system. Methodological approach and application to the French health care system. Health Policy. 49: 161177.
Svrcek M, Sabourin JC. 2002 Immunohistochemistry and genotype analysis of tumors. First part: Which future for the immunochemical diagnosis of cancer? Ann Pathol. 22: 102112.
Tubs RR, Pettay JD, Roche PC. 2001 Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 10: 27142721.
Vang R, Cooley LD, Harrison WR, Reese T, Abrams J. 2000 Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. Am J Clin Pathol. 113: 669674.
Vincent-Salomon A, MacGrogan G, Couturier J, et al. 2003 Calibration of immunohistochemistry for assessment of HER2 in breast cancer: Results of the French multicentre GEFPICS study. Histopathology. 42: 337347.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed